Canadian pharmaceutical giant Apotex has announced a significant strategic acquisition, agreeing to purchase Cumberland Pharmaceuticals’ entire portfolio of branded commercial…
Read More
AI Governance and Trust: The Bedrock for Scaling Innovation in Drug Development
The accelerating adoption of artificial intelligence (AI) within the pharmaceutical industry is not merely a technological advancement; it is a…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
In the wake of The New York Times’ April 2 profile, which painted MEDVi CEO Matthew Gallagher as a "vibe-coded…
Read More
Unlocking the Genetic Keys to GLP-1 Drug Efficacy and Side Effects
A groundbreaking study involving over 23andMe customers has identified genetic variations in two key genes that significantly influence both the…
Read More
The Non-GLP-1 Obesity Drug Market Set for Explosive 50-Fold Growth, Reaching $15.5 Billion by 2031
The global pharmaceutical market for obesity treatments is poised for a dramatic transformation, with a burgeoning segment of non-Glucagon-like peptide-1…
Read More
US President Signs Executive Order to Expedite Psychedelic Drug Review and Bolster Research
In a significant move poised to reshape the landscape of mental health treatment, U.S. President Donald Trump has signed an…
Read More
Can live cell dynamics fix drug discovery’s efficacy problem?
The pharmaceutical industry grapples with an intractable challenge: the escalating cost and protracted timelines of drug development, coupled with persistently…
Read More
From list price to net price: How finance leaders decode real drug costs
In the intricate landscape of the healthcare industry, discussions surrounding drug pricing often commence and conclude with the enigmatic "list…
Read More
Daiichi Sankyo Partners with Interna Therapeutics to Revolutionize Targeted Drug Delivery with Molecular Nano Motor Technology
Boston, MA & Tokyo, Japan – April 17, 2026 – In a significant move to enhance the precision and efficacy…
Read More
Kailera Therapeutics Secures $625 Million in Landmark IPO to Accelerate Obesity Drug Development
Obesity-focused biotechnology firm Kailera Therapeutics has successfully launched its Initial Public Offering (IPO), raising an impressive $625 million. This significant…
Read More
